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Abstract Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease. RA mainly affects the joints, with
inflammation of the synovial membrane, characterized by hyperplasia, neo-angiogenesis, and immune cell
infiltration that drives local inflammation and, if untreated, can lead to joint destruction and disability. In
parallel to the well-known clinical heterogeneity, the underlying synovitis can also be significantly
heterogeneous. In particular, in about 40% of patients with RA, synovitis is characterized by a dense
lymphocytic infiltrate that can acquire the features of fully functional tertiary lymphoid organs (TLO).
These structures amplify autoimmunity and inflammation locally associated with worse prognosis and
potential implications for treatment response. Here, we will review the current knowledge on TLO in RA,
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24 Abstract Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease.
25 RA mainly affects the joints, with inflammation of the synovial membrane, char-
26 acterized by hyperplasia, neo-angiogenesis, and immune cell infiltration that drives
27 local inflammation and, if untreated, can lead to joint destruction and disability. In
28 parallel to the well-known clinical heterogeneity, the underlying synovitis can also
29 be significantly heterogeneous. In particular, in about 40% of patients with RA,
30 synovitis is characterized by a dense lymphocytic infiltrate that can acquire the
31 features of fully functional tertiary lymphoid organs (TLO). These structures
32 amplify autoimmunity and inflammation locally associated with worse prognosis
33 and potential implications for treatment response. Here, we will review the current
34 knowledge on TLO in RA, with a focus on their pathogenetic and clinical
35 relevance.36
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38 Rheumatoid Arthritis (RA) is the most common autoimmune disease, affecting up
39 to 1% of the population worldwide (Smolen et al. 2016). Although RA is well
40 recognized as a systemic disease, its main feature is the chronic inflammation of the
41 synovial membrane, which is characterized by infiltration of immune cells, cellular
42 hyperplasia, and neo-angiogenesis (McInnes and Schett 2011, 2017). Ongoing
43 synovitis and its corresponding clinical features of joint pain and swelling are the
44 main causes of functional disability in patients with RA. Despite the availability of
45 effective medications, in a large proportion of patients, the treatments fail to control
46 the inflammatory response. When un-optimally controlled, synovial inflammation
47 can progress and ultimately lead to joint destruction and permanent disability. Such
48 inconsistent response to treatment has been attributed at least in part to the clinical
49 and physiopathological heterogeneity of RA. In fact, similar to other autoimmune
50 diseases, under the umbrella of RA, we are grouping a diverse spectrum of patients
51 with different clinical features, which are mirrored by significant differences in
52 terms of pathogenesis and, therefore, variable response to targeted treatments. For
53 example, it is well recognized that the positivity for anti-citrullinated protein
54 antibodies (ACPA) identifies a group of patients—around 70%- with a clinical
55 phenotype of highly aggressive and destructive disease (Willemze et al. 2012). In
56 line with its marked clinical heterogeneity, a variable degree of immune cell
57 infiltration has been described in the synovia of RA patients and has been recently
58 linked to distinct clinical features, including disease severity, progression, and
59 treatment response.
60 2 The Synovial Membrane as Site of Inflammation in RA
61 The main physiopathological feature of RA is the inflammation of the synovial
62 membrane (SM). In physiological condition, the SM is a composed by an intimal
63 layer formed of synoviocytes, also known as fibroblast-like synoviocytes (FLS),
64 which are specialized fibroblast-like cells with the main function of producing the
65 synovial fluid that lubricates and nourish the avascular articular surfaces. Below the
66 thin layer of FLS, there is a sub-intimal layer composed by connective tissues,
67 scattered infiltrating macrophage-like cells, and blood vessels. During RA, the
68 synovial membrane undergoes the following changes: (i) infiltration of immune
69 cells, including cells of innate (e.g., macrophages, natural killer [NK] cells, innate
70 lymphoid cells, dendritic cells, mast cells) and adaptive immunity (e.g., B and T
71 lymphocytes, plasma cells); (ii) proliferation of FLS, leading to the thickening of
72 the intimal layer, and (iii) growth of new blood vessels (neo-angiogenesis) which
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73 further sustains the infiltration of immune cells, thus facilitating the perpetuation of
74 the inflammatory response. Despite the enormous advancements in our under-
75 standing of the pathogenesis of RA, leading us to recognize a number of genetic
76 and environmental factors contributing to its pathogenesis, the initial trigger of
77 synovial inflammation is currently unknown. Also, we do not know whether the
78 first hit happens directly in the joints or somewhere else, such as the lungs or other
79 organs. However, once the inflammatory response is triggered and gets perpetuated,
80 synovitis represents the main feature of RA, thus the study of synovial inflamma-
81 tion is of utmost importance to improve our understanding of RA (Pitzalis et al.
82 2013).
83 2.1 Histological Patterns of Synovial Inflammation
84 The infiltration of immune cells is one of the main features of RA synovitis. In line
85 with the clinical heterogeneity of the disease, a variable degree of immune cell
86 infiltration in synovia has been described. Despite the complexity and partial
87 overlap of immune cell infiltration, the parallel study of large numbers of synovial
88 samples from patients with early untreated RA (Humby et al. 2019) has allowed to
89 describe three distinct groups based on the patterns of immune cell infiltration in
90 synovia: (1) lympho-myeloid, dominated by lymphoid lineage infiltration (T cells,
91 B cells, plasma cells) in addition to myeloid cells; (2) diffuse-myeloid, with myeloid
92 lineage predominance but poor in B cells/plasma cells and (3) pauci-immune,
93 characterized by scanty immune cells and prevalent stromal cells. Within the
94 lympho-myeloid group, the infiltrating B cells, T cells, and plasma cells often
95 organize into aggregates that resemble the lymphoid follicles of secondary lym-
96 phoid organs, acquiring features such as segregation of T cells and B cells, the
97 presence of high endothelial venules (HEVs), and follicular dendritic cells (FDCs)
98 networks. Although TLO can also be detected at extra-articular sites, including the
99 lungs (Barone et al. 2015) and bone marrow (Bugatti et al. 2005) of RA patients,
100 they mainly form within the sublining of the synovial tissue, where they have been
101 described in about 40% of patients with early untreated RA (Pitzalis et al. 2013).
102 A representative example of TLO is offered in Fig. 1a–c, including a schematic
103 representation of their organization in Fig. 1d, with additional details in Fig. 2. In
104 the next paragraphs, we will describe the ontogeny of tertiary lymphoid organs in
105 RA, their functions, and their correlation with clinical features and disease prog-
106 nosis, including response to treatment.
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Fig. 1 Tertiary lymphoid organs in synovia. a Immunohistochemical staining of synovial
membrane, b color deconvolution of the images in (a), c overlap of the above images, and
d schematic representation of the organization of TLO in synovia, with FDC in yellow, B cells in
green, T cells in red, and plasma cells in blue
Fig. 2 Schematic representation of synovial TLOs and immune cells contributing to their
development. Tfh = T follicular helper cells; Tfr = T follicular regulatory cells, Th17 = T helper
cells 17, NK = Natural killer cells; LTi = Lymphoid tissue inducer
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107 3 Synovial Tertiary Lymphoid Organs in RA
108 3.1 The Development and Regulation of Synovial Tertiary
109 Lymphoid Organs in RA
110 3.1.1 Chemokine and Lymphotoxin Beta
111 One of the initial steps in the formation of TLO is the infiltration of lymphoid cells
112 into the synovia, which is driven by the inflammatory milieu produced by FLS and
113 innate immunity cells. As the inflammatory process becomes chronic, however, a
114 number of specific mediators are required for the formation of TLO, such as
115 lymphotoxin-b (LTb), CXCL13, CCL19, and CCL21 (Corsiero et al. 2012). The
116 development of TLO largely mirrors the ontogeny of secondary lymphoid organs,
117 thus most of our knowledge on TLO development is derived from the study of
118 secondary lymphoid organs, where animal models have identified a number of
119 stimuli which are essential for the development of secondary lymphoid organs
120 (Randall et al. 2008; Drayton et al. 2006). Among these stimuli, the primum movens
121 has been recognized to be the production of lymphotoxin-b from so-called lym-
122 phoid tissue inducer (LTi) cells (Bar-Ephraim and Mebius 2016), which in turns
123 leads to the production of lymphoid chemokines (CXCL13, CCL19, and CCL21)
124 from lymphoid tissue organizers and mesenchymal cells. Although the presence of
125 many of these lymphogenic stimuli has been confirmed in TLO in rheumatoid
126 synovium (Bugatti et al. 2014; Manzo et al. 2007), the initial trigger of TLO
127 formation in RA has not been identified. Several immune cells have been shown to
128 be a source of lymphoid chemokines, and some of these key cells are represented in
129 Fig. 2b. Among the various mediators, CXCL13 produced by follicular dendritic
130 cells (Takemura et al. 2001) and other immune cells plays a pivotal role in deter-
131 mining the spatial organization of TLO, inducing the segregation of B cells within
132 the germinal center, which is an essential drive for affinity maturation and antigenic
133 selection (De Silva and Klein 2015). In line with its pivotal role, serum levels of
134 CXCL13 have been associated with the presence of synovial TLO in patients with
135 RA (Bugatti et al. 2014; Dennis et al. 2014).
136 3.1.2 T Follicular Helper Cells
137 In recent years, a specialized class of T helper cells, named T follicular helper cells
138 (Tfh), has been recognized for their central role in sustaining B cell activation and
139 differentiation in the germinal center (GC) reactions in secondary lymphoid organs.
140 Tfh cells are specialized T helper cells that upon priming by antigen presenting cells
141 (APCs) acquire the expression of CXCR5, the receptor for CXCL13, enabling them
142 to migrate into the B cell area of GC.
143 The ectopic expression of CXCL13 has been described in RA synovium (Manzo
144 et al. 2005, 2008) and has been shown to induce TLO formation and recruits B cells
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145 to non-lymphoid tissues in mice (Luther et al. 2000). In fully formed GC, Tfh cells
146 support somatic hypermutation of auto-reactive B cells and plasmablast generation
147 directly in the diseased tissues mainly through the production of IL-21. The latter is
148 Tfh signature cytokine, known to be a potent cofactor for B cell survival, prolif-
149 eration and plasma cell differentiation, in particular in the context of CD40
150 co-stimulation and in synergy with B cell activating factor (Karnell and Ettinger
151 2012; Liu et al. 2015).
152 Importantly, because of the role of IL-21 and Tfh cells in supporting GC
153 response, they have been implicated in the development of TLO in rheumatic
154 autoimmune diseases, including RA, as represented in Fig. 2.
155 Data in animal models of arthritis identified a number of Tfh-associated markers
156 during the development of inflammatory arthritis. In particular, CXCR5 has been
157 shown to be an essential factor for the development of inflammatory arthritis:
158 CXCR5-deficient animals or lacking CXCR5 on T cells are resistant to RA,
159 showing impaired GC response (Moschovakis et al. 2017). Also, selective defi-
160 ciency in T helper cells of SLAM-associated protein (SAP), required for the B/T
161 cell interaction, thus essential for Tfh differentiation, protects mice from RA, further
162 supporting the pathogenic role of ectopic GC formation (McCausland et al. 2014).
163 In parallel, IL-21 and its receptor are highly expressed in synovial tissue of
164 patients with RA (Jüngel et al. 2004; Kwok et al. 2012), and increased IL-21
165 expression is associated with synovial TLO (Jones et al. 2015). IL-21R
166 up-regulation is mainly described on macrophages and fibroblast with an acti-
167 vated phenotype (Jüngel et al. 2004), and IL-21 has been involved in the devel-
168 opment of articular damage by promoting both osteoclastogenesis (Kwok et al.
169 2012) and metalloproteinase release by fibroblast-like synoviocytes (Xing et al.
170 2016). Finally, Tfh cells are also enriched in the synovia of patients with RA, while
171 almost absent in osteoarthritis and normal synovium (Penatti et al. 2017; Chu et al.
172 2014).
173 In addition to conventional CXCR5+ Tfh cells, a population of T helper cells
174 lacking CXCR5 expression and producing CXCL13 has been also described in the
175 synovia of RA patients (Manzo et al. 2008). A recent breakthrough publication has
176 shed new light on these cells, which have been re-named as PD1+ CXCR5—T
177 peripheral helper cells (Tph), since they have been found in the synovia but also in
178 the peripheral blood of patients with RA and their ability to induce the activation of
179 B cells has been confirmed in vitro (Rao et al. 2017). Similar to GC-Tfh, these cells
180 are an important source of CXCL13, support synovial B cell proliferation and
181 activation through IL-21 production and SLAMF5 receptor ligation, and co-localize
182 with B cells in synovial TLO (Rao et al. 2017). Although Tfh and Tph cells share
183 the main markers, the tissue localization, and the ability to support B cell activation,
184 it is unclear whether Tph in RA are Tfh cells with impaired CXCR5 expression, or a
185 more distantly related cell type. Despite the evidence of Tfh and Tph contribution to
186 the pathogenesis of RA, the functional link between these cells and TLO formation
187 remains to be elucidated, as well as their contribution to the local production of
188 autoantibodies within TLO.
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189 Additionally, although the enrichment of Tfh in RA synovium has been well
190 described, there are conflicting data regarding circulating Tfh cell frequency
191 [comprehensively reviewed in (Gensous et al. 2018)]. Some authors reported IL-21
192 directly correlating with the frequency of Tfh-like cells, with IL-21 level and
193 number of Tfh-like cells associated with higher titer of anti-CCP antibodies and
194 disease activity score in RA (Ma et al. 2012). The circulating counterpart shares
195 phenotypic and functional features with tissue Tfh cells, except for the expression
196 of prototypical Tfh transcription factor B cell lymphoma protein 6 (Bcl-6), but their
197 biology is still poorly defined. Data from SAP-deficient mice show how these cells
198 are committed to Tfh lineage and are generated prior the GC response (He et al.
199 2013; Tsai and Yu 2014). Moreover, it is still unclear if circulating Tfh can reflect
200 an ongoing humoral activity.
201 3.1.3 Other Pro-inflammatory Cytokines and Cells
202 It is now clear that a number of other pro-inflammatory cytokines, such as IL-17,
203 IL-21, IL-22, IL-23, and TNFa, are also critical for lymphoid neogenesis in
204 autoimmune diseases (Jones and Jones 2016).
205 The IL-23–IL-17 pathway has been involved in the initiation and perpetuation of
206 TLO, and several cells of the innate and adaptive immunity are able to produce
207 IL-17. In particular, a subset of adult innate lymphoid cells [type-3 innate lymphoid
208 cells (ILC3 cells)] can produce IL-17 in the initial phases of TLO formation (Sawa
209 et al. 2010). Accordingly, IL-17 positive cells are observed in the proximity of TLO
210 in RA synovia (Chabaud et al. 1999), and the activation of the IL-23–IL-17
211 pathway correlates with the presence of synovial TLO (Cañete et al. 2011).
212 Another important aspect is the potential plasticity between other T helper
213 subsets and the Tfh. In fact, several other subsets, including Th17 cells, Th1 and
214 Th2, have been described to acquire Tfh-like phenotype (Ueno et al. 2015). For
215 example, Tfh2 and Tfh17, but not Tfh1, are able to secrete IL-21 and induce naïve
216 B cells to secrete class-switched immunoglobulin (Ig) (Morita et al. 2011).
217 Within RA synovium, proliferation of fibroblast-like synoviocytes is sustained
218 by IL-22, a cytokine required for the development and maintenance of TLO. IL-22
219 role in ectopic lymphoneogenesis comes from data in experimental models of
220 inducible TLO in salivary glands, mimicking TLO formation in Sjogren’s syn-
221 drome salivary glands. In this animal model, IL-22 is able to directly induce
222 CXCL13 production in a subset of GP38+ stromal cells through phosphorylation of
223 signal transduced and activator of transcription 3 (STAT3) (Barone et al. 2015).
224 Once lymphocytes are recruited, IL-22, together with LTa1b2, supports also pro-
225 liferation of a population of podoplanin (pdpn)-positive stromal cells,
226 over-expressing IL21R, into a network of immunofibroblasts that are able to sup-
227 port the earliest phases of TLS establishment (Nayar et al. 2019) in the same model.
228 In RA synovium, IL-22 expression and IL-22 receptor on fibroblast-like synovio-
229 cytes have been reported (Ikeuchi et al. 2005), suggesting its contribution to the
230 maintenance of TLO. In particular, IL-22 expression is increased in cells expressing
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231 the long isoform of complement receptor type 2 (Cr2, also known as CD21) (Cañete
232 et al. 2011), usually present in networks of stromal-derived follicular dendritic cells
233 (FDCs), that contribute to the presentation of immune complexes necessary to
234 generate activated B cells, in TLO. In synovial tissue, IL-22 is also produced by NK
235 cells (Zhu et al. 2015). NK cells are innate immune lymphocytes with cytolytic and
236 immune-regulatory activities representing a significant proportion (8–25%) of
237 immune infiltration in synovial fluid of RA patients, identified in the joints in the
238 early stage of RA development (Tak et al. 1994). Initially, NK cells were described
239 in RA pathogenesis for their production of cytotoxic serin protease granzyme-A and
240 B and pro-inflammatory cytokines, such as IL-1 and TNFa as dominant mediators
241 of proliferative synovitis in RA (Klimiuk et al. 1997), supporting ocleoclastogen-
242 esis and thus involved in the development of articular damage (Kotake et al. 2001).
243 In fact, increased production of IFNc and TNFa characterizes synovial fluid NK
244 cells of erosive RA patients with joint damage in comparison with non-erosive RA
245 (Yamin et al. 2019). Recent evidence suggests that NK cells may support TLO
246 maintenance within RA synovium as a subset of NK cells expressing a natural
247 cytotoxicity receptor NKp44 which is able to produce IL-22 (Zhu et al. 2015).
248 NKp44+ NK cells are enriched in both peripheral blood and synovium of RA
249 patients secreting IL-22 and TNFa, which in vitro studies showed to support
250 RA FLS proliferation (Ren et al. 2011), through the activation of STAT3 pathway
251 (Zhu et al. 2015). IL-22 induced proliferation of synovial fibroblast, an effect that
252 was inhibited by neutralizing antibodies targeting IL-22 and TNFa (Ren et al.
253 2011). Thus, NK cells may participate in TLO organization supporting the prolif-
254 eration of synovial fibroblasts responsible for the local secretion of chemoattractant
255 molecules and, as consequence, lymphocytes recruitment.
256 In addition to cells of the adaptive immunity, many other innate immunity cells
257 and the stromal compartment have been shown to contribute to the development of
258 synovial TLO (Barone et al. 2016).
259 Fibroblast-like synoviocytes (FLS), for example, have been shown to produce
260 the T cell/dendritic cell chemoattractant CCL21 (Manzo et al. 2007) and express
261 CXCL12 and IL-7, involved in immune cell retention and lymphoid-like
262 microanatomical organization (Timmer et al. 2007; Bradfield et al. 2003).
263 Recently, we have also shown a strong association between synovial mast cells
264 (MCs) and the presence of TLO in a large cohort of patients with early RA
265 (Rivellese et al. 2018). MCs were also found to induce B cell activation and
266 differentiation in vitro, including the production of ACPA autoantibodies. Finally,
267 in animal models of inducible TLO (IL27R knockout), we confirmed the associa-
268 tion of MCs with TLO. Overall, this points out to the relevance of MCs as potential
269 contributors to the formation of TLO, although additional studies are needed to
270 confirm their functional relevance (Rivellese et al. 2017, 2019b).
8 F. Rivellese et al.






















271 3.1.4 Negative Regulators of TLO Including Tfr
272 In addition to the mediators and pathways acting as positive regulators of TLO,
273 several cells and cytokines have been characterized as negative regulators of TLO
274 development.
275 For example, IL-27, an heterodimeric cytokines part of the IL-12 family
276 (Yoshida and Hunter 2015), has been recently identified as a negative regulator of
277 TLO. In fact, animals with knockout of the IL27Ra develop a severe form of
278 antigen-induced arthritis, including the development of synovial TLO (Jones et al.
279 2015). Importantly, synovial TLO are not normally produced in animal models of
280 arthritis; thus, the identification of these structures in IL-27Ra knockout animals
281 points to the relevance of IL-27 as a regulator of TLO development. Accordingly, in
282 patients with RA, IL-27 was found to be inversely correlated with TLO and with
283 TLO-related gene signatures. Finally, both in clinical and experimental arthritis,
284 synovial TLO coincided with an increased local expression of cytokines and
285 transcription factors of the Th17 and T follicular helper (Tfh) cell lineages, where
286 IL-27 is able to inhibit the differentiation of Th17 cells, in line with previous
287 evidence (Stumhofer et al. 2006).
288 As local counterpart of the circulating T regulatory cells, T follicular regulatory
289 cells (Tfr) have been recently described within GCs, including GCs in TLO. Tfr
290 cells are able to prevent the differentiation of auto-reactive B cells (Wu et al. 2016;
291 Botta et al. 2017), by regulating Tfh cells, but also by directly inhibiting B cell
292 activation (Wing et al. 2014).
293 Although the relevance of Tfr cells in the regulation of GCs in animal models is
294 well established (Linterman et al. 2011), the involvement of Tfr cells in human
295 autoimmune disease, including RA, is still unclear.
296 Several studies have reported decreased levels of Tfr in patients with active RA
297 and, accordingly, negative correlations with autoantibodies and disease activity
298 (Romão et al. 2018; Niu et al. 2018). On the other hand, increased levels of Tfr
299 were found in patients who were in remission (Liu et al. 2018). Using animal
300 models of autoimmunity with spontaneous development of GCs, IL-21 was shown
301 to induce an unbalance between Tfh and Tfr, increasing the formation of GCs,
302 while administration of Tfr was able to restore Tfh:Tfr ration and suppress GC
303 responses (Ding et al. 2014).
304 Another group found that the resolution of collagen-induced arthritis following
305 administration of intravenous immunoglobulins was accompanied by an increase of
306 Tfr cells (Lee et al. 2014). Taken together, this suggests that the reduction of
307 circulating Tfr cells is associated to the development of RA and that restoration of
308 Tfr cells could potentially improve autoimmune responses.
309 In line with this, monitoring the ratio between Tfr and Tfr could be useful in
310 patients with RA, as confirmed by a several observations (Niu et al. 2018; Wang
311 et al. 2019).
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312 As for the function of Tfr in RA, these cells have been shown to have sup-
313 pressive effects in vitro, which were enhanced in patients in remission (Liu et al.
314 2018). However, it has also been speculated that Tfr in autoimmune diseases might
315 be functionally deficient (Fonseca et al. 2017).
316 3.2 The Function of Tertiary Lymphoid Organs in RA
317 As TLO mirrors secondary lymphoid organs in their ontogeny and maturation, it is
318 expected that they also recapitulate the main functions of secondary lymphoid
319 organs, which is supporting germinal centers (GC) reaction toward maturation of B
320 cells and antibody production.
321 Within a considerable proportion of TLO forming in rheumatoid synovium,
322 ectopic GC reactions take place similar to secondary lymphoid organs (Bombardieri
323 et al. 2017). Many of RA-associated autoantibodies are high affinity IgG (e.g.,
324 ACPA) (van Delft and Huizinga 2020), and B cells forming TLO are auto-reactive
325 and somatically mutated (Humby et al. 2009), indicating the involvement of a GC
326 response in RA progression. Indeed, TLO in RA synovium can display functional
327 features of germinal centers, like the expression of the enzyme activation-induced
328 cytidine deaminase (AID) involved in in situ B cell affinity maturation and clonal
329 selection (Humby et al. 2009).
330 Accordingly, the analysis of B cells isolated from the synovia of patients with
331 RA has confirmed the generation of synovial plasma cells from locally activated B
332 cells (Scheel et al. 2011), and the local production of class-switched autoantibodies
333 in rheumatoid synovium has been demonstrated (Humby et al. 2009). Also, we
334 have recently demonstrated that the presence of synovial TLO in early untreated
335 RA is associated with autoantibody positivity (Humby et al. 2019). Interestingly,
336 this is in contrast with previous data that failed to show an association between TLO
337 and autoantibody positivity (Thurlings et al. 2008). Recently, comparing two large
338 cohorts of patients with early and established RA, we were able to confirm the
339 strong association between TLO and autoantibody positivity in early RA that could
340 not be observed in established RA, thus explaining the previous findings, possibly
341 because of treatment effect or other biases from long-standing diseases (Rivellese
342 et al. 2019a).
343 Importantly, the initiation of a germinal center reaction requires antigen pre-
344 sentation to B cells. In RA, the aberrant immune response against citrullinated
345 proteins culminating in the production of anti-citrullinated protein antibodies
346 (ACPA) is well recognized as a key pathogenetic feature (Derksen et al. 2017).
347 Accordingly, citrullinated proteins have been described in the synovia of RA
348 patients (Baeten et al. 2001) together with PAD enzymes, which are responsible for
349 citrullination (De Rycke et al. 2005). The specificity of synovial citrullinated pro-
350 tein has been challenged (Vossenaar et al. 2004), but this does not come as a
351 surprise since citrullination and other post-translational modifications of proteins
352 are recognized as physiological processes (Trouw et al. 2017). On the contrary, the
10 F. Rivellese et al.






















353 aberrant immune response to modified proteins represents the hallmark of RA, and
354 accordingly, the local production of ACPA in synovia has been confirmed (Humby
355 et al. 2009; Amara et al. 2013; Masson-Bessière et al. 2000). Finally, several groups
356 have been able to isolate ACPA-producing B cell clones from the synovia and
357 synovial fluid of patients with RA (Germar et al. 2019; Corsiero et al. 2016, 2018).
358 3.3 The Clinical Relevance of Tertiary Lymphoid Organs
359 in RA
360 3.3.1 TLO and Disease Severity
361 Early studies on the analysis of synovial membrane relied on the use arthroscopy to
362 obtain synovial samples. These analyses pointed out a marked heterogeneity in
363 terms of synovial inflammation, particularly in the degree of immune cell infiltra-
364 tion, with the description of aggregates of lymphoid cells in a proportion of patients.
365 However, when looking for an association with clinical features, these studies
366 yielded contradictory results: some found an association of lymphoid aggregates
367 with disease severity and autoantibody positivity (Humby et al. 2019; Bugatti et al.
368 2014; Orr et al. 2017) and others did not (Thurlings et al. 2008; Cantaert et al. 2008;
369 Van De Sande et al. 2011) (Table 1). These inconsistencies could be explained by a
370 number of biases: (i) the exclusive analysis of large joints, in which there can be
371 commonly overlapping osteoarthritis and are not the most representative of the
372 inflammatory process in RA (Linn-Rasker et al. 2007) (ii) the inclusion of patients
373 with long-standing disease, with the obvious bias of treatment and disease duration,
374 and (iii) the lack of a gold standard for the histological assessment of immune cell
375 infiltration (Humby et al. 2016).
376 The development of minimally invasive techniques such as ultrasound-guided
377 synovial biopsies has overcome most of these limitations, as it made possible to
378 obtain synovial tissues from small joints of a large cohort of patients with early RA
379 and, very importantly, prior to treatment star. Thus, it is not surprising that the
380 recently published analyses on this cohort highlighted a strong association with
381 disease severity and autoantibody positivity (Humby et al. 2019). Interestingly, a
382 direct comparison of early and established RA, using a validated semi-quantitative
383 score for the assessment of B cells, showed that while in early RA the presence of B
384 cell-rich synovitis was associated with disease severity, this was not the case in
385 established RA, possibly explaining the discrepancies from previous studies ana-
386 lyzing patient with different disease duration Rivellese et al. (2019a).
387 When analyzing exclusively patients with early untreated RA, our group has
388 recently shown that patients with a synovial lympho-myeloid pathotype, charac-
389 terized by the presence of B and T cell aggregates, have significantly higher disease
390 severity, autoantibody positivity, and baseline erosive load (Humby et al. 2019).
391 Furthermore, molecular analyses showed that myeloid- and lymphoid-associated
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392 genes strongly correlate with disease activity and acute phase reactants. Another
393 more recent publication in early RA has further highlighted the value of synovial
394 tissue analyses in refining the diagnosis of RA vs undifferentiated arthritis.
395 Moreover, deep phenotyping of synovial tissue by molecular analyses has
396 identified specific gene signatures associated with clinical phenotype. In particular,
397 for example, peripheral blood interferon response genes were associated with the
398 lymhpo-myeloid pathotype, while synovial plasma cell signature was associated
399 with progression of structural damage (Lewis et al. 2019). Additional analyses from
400 the Accelerating Medicine Partners group, by integrating single cell RNA
401 sequencing and mass cytometry, have recently identified unique cell population
402 expanded in RA synovia that allow to distinguish the degree of synovial inflam-
403 mation (Rao et al. 2017; Zhang et al. 2019). Specific cell populations included HY1
404 (CD90) +HLA-DRAhi sublining fibroblasts, IL1B+ pro-inflammatory monocytes,
405 ITGAX + TBX21 + autoimmune-associated B cells, and PDCD1+ peripheral
406 helper T (TPH) cells and follicular helper T (TFH) cells. The latter, in particular, are
407 essential for the formation of TLO and have been already discussed in the previous
408 paragraph. However, to date, little is known about the association of these cell types
409 with disease features, such as disease severity, progression, and response to treat-
410 ment. In the near future, it will be of utmost importance to confirm the relevance of
411 these immune populations, by studying their association with clinical phenotype in
412 larger cohorts of patients with RA.
413 3.3.2 TLO as Direct Therapeutic Targets
414 Because of their well-established relevance in driving the pathogenesis of RA and
415 their association with worse disease outcomes, several strategies aiming at targeting
416 TLO in RA have also been tested.
417 A number of studies have attempted to target mediators that are relevant in the
418 formation or maintenance of TLO. The modulation of the IL-21/IL-21R pathway as
419 a treatment strategy was first tested in experimental models of RA. IL-21R defi-
420 ciency in the K/BxN mouse model of inflammatory arthritis (Kim et al. 2009) and
421 antigen-induced arthritis (Roeleveld et al. 2017) is sufficient to block RA initiation,
422 while the blockade of the IL-21/IL-21R pathway ameliorates disease in
423 collagen-induced arthritis models treated with murine IL-21R Fc fusion protein
424 (Young et al. 2007). However, there are still no data in patients with RA on the
425 blockade of IL-21/IL-21R.
426 Some other molecules have been already tested in patients, but results have not
427 been particularly striking, as in the case of inhibiting LTb, which did not show
428 clinical efficacy (Bienkowska et al. 2014). Similarly, drugs inhibiting IL-17 and
429 IL-12/IL-23 showed little or no differences compared with placebo in RA
430 (Kerschbaumer et al. 2019). This is in contrast with data on seronegative arthritis,
431 where inhibition of IL-17 and its axis proved to be extremely effective, although it
432 has been suggested that the analysis of targeted expression of these molecules could
433 potentially help in predicting treatment response (Boutet et al. 2018).
14 F. Rivellese et al.






















434 Importantly, none of the above studies targeting mediators involved in TLO
435 formation or maintenance in RA has stratified patients on the basis of TLO pres-
436 ence, which could have helped in selecting patients with higher chances of
437 response.
438 3.3.3 TLO as Predictors of Treatment Response
439 As highlighted in the previous paragraphs, the presence of TLO is able to identify a
440 subset of RA patients with a specific disease phenotype, specifically higher disease
441 activity and higher prevalence of autoantibodies. Therefore, it is plausible to
442 hypothesize that the presence of TLO could help to predict treatment response.
443 A number of studies have explored the analyses of synovial tissues to predict
444 treatment response. However, relatively few included the systematic analysis of
445 TLO. Futhermore, because of the relatively small number of patients, the incon-
446 sistency in the definition of TLO, and the use of different time points for repeated
447 biopsy, most of the results are fragmented and difficult to interpret.
448 Canete et al., for example, demonstrated significantly lower response in patients
449 who were TLO positive despite a significantly higher use of anti-TNFa agents.
450 (Cañete et al. 2009) By linear regression, TLO positive were found to predict lack
451 of response to anti-TNFa. In this study, however, patients started sequential treat-
452 ment with escalation to anti-TNFa in non-responders, and therefore, there could
453 have been a selection of TLO + patients as the most severe, thus non-responders.
454 On the contrary, Klaasen et al., by analyzing synovial samples obtained before
455 and after standardized treatment with infliximab in a cohort of 97 patients, found
456 that the presence of TLO at baseline was a highly significant predictor of the
457 clinical response to anti-TNF treatment (Klaasen et al. 2009).
458 More recently, Dennis et al. provided the molecular confirmation of the histo-
459 logical pathotypes previously described by histology. In addition, by analyzing the
460 data from a previous cohort undergoing treatment with infliximab, they were able to
461 identify TLO signature as predictor of response to TNFi (Dennis et al. 2014). The
462 limitation of this manuscript consisted in the analysis of synovial samples obtained
463 from arthroplasty, thus without standardization of treatment.
464 The observations published from our early RA cohort allowed to overcome such
465 limitations and have shown a reduction of lymphoid-associated genes in EULAR
466 good responders to csDMARDs (Humby et al. 2019). Similarly, molecular analyses
467 by RNAseq identified a number of cell modules, including B cells, in association
468 with B response to csDMARDs (Lewis et al. 2019). Importantly, these data come
469 from the analysis of synovial tissue obtained by US-guided synovial biopsies in
470 untreated patients with early Rheumatoid Arthritis, thus eliminating the bias of
471 long-standing disease, treatment or the exclusive inclusion of large joints in studies
472 based on arthroscopy.
473 In recent years, continuing on the same line, two international consortia have
474 driven the delivery of the first two large-scale biopsy-driven RCTs in Rheumatoid
475 Arthritis. As part of a study funded by the UK National Institute of Health AQ2
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476 Research, a randomized, open labeled study in anti-TNFa inadequate responders to
477 investigate the mechanisms for Response—resistance to rituximab versus tocili-
478 zumab in RA (R4-RA), a total of 165 patients failing treatment with TNFi have
479 been recruited. Promising preliminary results were presented at the ACR 2019,
480 while the trial is currently being analyzed and final results will be soon published.
481 Similarly, as part of the MRC and versus arthritis-funded consortium maximizing
482 therapeutic utility in RA (MATURA), the stratifying therapies for rheumatoid
483 arthritis by pathobiology (STRAP) RCT has enrolled a total of 226 patients who
484 failed csDMARDs and is due to being completed in the last quarter of 2020.
485 These studies have been appropriately powered and thus will hopefully give
486 clear answers on the utility of synovial biopsy analysis in predicting treatment
487 response in RA. Specifically, the studies aimed at understanding if patients lacking
488 synovial B cells have a lower response to B cell targeted treatment (Rituximab) as
489 opposed to other treatments. At the same time, the studies will provide invaluable
490 information to answer additional research questions, including the association of
491 TLO with disease severity, progression, and treatment response.
492 4 Conclusions
493 Here, we offered a comprehensive review on the relevance of synovial TLO in RA.
494 The data presented indicate that the ontogeny of TLO resembles the development of
495 secondary lymphoid organs, since many of the mediators known to be involved in
496 lymphoneogenesis have been identified in the synotia of RA patients. Importantly,
497 these structures are fully functional, as they induce the local maturation of B cells
498 toward the production of autoantibodies. Their presence has been described in
499 about 40% of patients with RA from early disease stages and has been strongly
500 associated with disease severity and progression. Despite the availability of several
501 drug treatments that can directly or indirectly target TLO and their components, a
502 stratified medicine approach is needed to fully appreciate the potential effect of such
503 treatments.
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